Does fluoxetine cause growth retardation in children and adolescents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does Fluoxetine Cause Growth Retardation?

Yes, fluoxetine can cause growth retardation in children and adolescents, with evidence showing dose-dependent reductions in both height gain and weight gain during treatment, though the clinical significance and long-term impact on final adult height remain uncertain.

Evidence from Clinical Studies

The most recent and highest-quality research demonstrates clear growth effects:

Recent prospective data 1 from 2024 shows that fluoxetine (and sertraline) reduce height gain and IGF-1 concentration in a dose-dependent manner during puberty. In this 6-month cohort study of 8-15 year-olds in Tanner stages 2-4, SSRI treatment was associated with smaller growth in height compared to unmedicated controls, with the dose-by-time interaction inversely associated with height Z-score.

A 19-week controlled trial 2 found that fluoxetine-treated patients gained statistically significantly less height (1.0 cm vs 2.1 cm for placebo, p=0.004) and weight (1.2 kg vs 2.3 kg for placebo, p=0.008) compared to placebo-treated patients. The study specifically noted that "during treatment with fluoxetine, the growth of child and adolescent patients should be monitored."

Mechanism and Clinical Implications

The growth suppression appears to operate through:

  • Reduced IGF-1 signaling: The 2024 study 1 demonstrated that SSRI dose was inversely associated with IGF-1 concentration (β = -63.5), suggesting interference with growth hormone pathways
  • Dose-dependent effects: Higher doses and longer duration of treatment are associated with greater growth suppression
  • Puberty-specific vulnerability: Effects appear most pronounced during Tanner stages 3-4 3

FDA Labeling and Guidelines

The FDA label for fluoxetine 4 does not specifically highlight growth retardation as a primary adverse effect, though it notes various adverse events in pediatric populations. However, fluoxetine is FDA-approved for treatment of MDD in children aged 8 years or older 5.

Comparison to Other Medications

For context, stimulant medications used in ADHD show similar patterns:

  • The MTA study 6 identified growth decrements of 1-2 cm from predicted adult height with stimulants
  • Atomoxetine 6 has been linked to growth delays in the first 1-2 years of treatment, with return to expected measurements after 2-3 years

Clinical Monitoring Recommendations

Based on the evidence, clinicians should:

  1. Monitor growth parameters regularly - Measure height and weight at baseline and every 3-6 months during fluoxetine treatment
  2. Consider dose optimization - Use the lowest effective dose, as growth effects are dose-dependent
  3. Pay special attention during puberty - Growth suppression appears most significant during active pubertal development (Tanner stages 2-4)
  4. Document growth trajectories - Plot height and weight on standardized growth charts and calculate Z-scores
  5. Reassess treatment necessity - Per guidelines 7, after 6-12 months of symptom remission, consider whether continued treatment is needed

Important Caveats

  • Long-term outcomes unclear: Whether these growth effects persist or affect final adult height requires longer-term studies 1, 2
  • Clinical significance uncertain: The magnitude of growth reduction (approximately 1 cm over 19 weeks) may not translate to clinically meaningful differences in final height
  • Risk-benefit consideration: The established benefits of fluoxetine for treating MDD in children 5 must be weighed against growth concerns, particularly given the serious morbidity and mortality risks of untreated depression

The evidence supports that fluoxetine does cause measurable growth retardation during treatment, but this should not automatically preclude its use when clinically indicated for depression. Close monitoring and dose optimization are essential components of safe prescribing in pediatric populations.

References

Related Questions

Could the decreased effectiveness of 20 mg immediate‑release methylphenidate in a 10‑year‑old be due to growth‑related changes in weight or body surface area?
How should I manage a 14-year-old with depression and anxiety on fluoxetine 20 mg daily (Prozac) and hydroxyzine 25 mg three times daily who presents with orthostatic dizziness, tinnitus, blurred vision, olfactory hallucinations of rubbing alcohol, recent syncope with a fall, and derealization, especially if her symptoms remain uncontrolled?
Can a 14-year-old patient take fluoxetine (Prozac) 60 mg daily?
Does methylphenidate cause growth suppression in children and adolescents?
Does sertraline (selective serotonin reuptake inhibitor) affect height in adolescents?
What is the appropriate oseltamivir dosage for an 18‑year‑old patient weighing 26 kg?
In a 7‑day‑old term neonate with failure to gain weight, projectile vomiting after most feeds, green stools, and a normal pyloric ultrasound, what is the most likely diagnosis and what are the appropriate next steps—including need for laboratory tests, urine studies, abdominal radiograph, or upper gastrointestinal series?
I have regular menstrual cycles that last only one day and are scanty (very light); what could be causing this and how should I manage it?
Is consuming an 8‑gram serving of trans fat from ghee, when homemade ghee is unavailable, safe or healthy?
What is the differential diagnosis for non‑bilious vomiting in a 7‑day‑old neonate?
How should I manage a patient with dysautonomia and spinal cord syndrome who has negative MRI, EMG, anti‑myelin oligodendrocyte glycoprotein (MOG) antibodies, neuromyelitis optica (NMO) antibodies, and oligoclonal bands?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.